Lee Cranmer, M.D., Ph.D.

(877) 460-4673
Lee Cranmer, M.D., Ph.D.
Medical Oncologist
Clinical Expertise
  • Sarcoma
  • Bone Cancers
  • Head and Neck Cancers
  • Melanoma
  • Skin Cancers
Academic Appointments
  • Vice Chair, Department of Medical Oncology & Therapeutics Research
  • Section Chief, Sarcoma Medical Oncology
  • Professor, Department of Medical Oncology & Therapeutics Research
Research Teams
Medical Oncology & Therapeutics Research
Sarcoma

Lee Cranmer, M.D., Ph.D., F.A.C.P., is a professor and section chief of sarcoma medical oncology and vice chair of the Department of Medical Oncology for City of Hope® Cancer Center Duarte clinical network, bringing a guiding hand and decades of experience to his work with every patient.

Dr. Cranmer attended medical school at the University of California, San Diego’s Medical Scientist Training Program. He completed his residency in internal medicine at the Mayo Clinic in Rochester, Minnesota and a fellowship in medical oncology at the University of Arizona Cancer Center in Tucson, where he then spent 15 years treating sarcoma and skin cancer patients. He also led the Sarcoma Program at the Fred Hutch Cancer Center in Seattle, Washington.

A seasoned health care leader and a fellow of the American College of Physicians, Dr. Cranmer has held multiple faculty positions at institutions throughout the Western United States and has served as principal investigator for more than 30 leading-edge clinical trials. He’s also a nationally recognized physician-scholar with nearly 100 publications to his name.

Location

Education & Experience

Degrees

  • 2017, Master of Public Health, Biostatistics, University of Arizona, Tucson, Arizona
  • 1998, Doctor of Medicine, University of California, San Diego La Jolla, California
  • 1997, Doctor of Philosophy, Biology, University of California, San Diego La Jolla, California
  • 1989, Master of Science, Parasitology, University of Liverpool, Liverpool, England
  • 1988, Bachelor of Arts, Harvard University, Cambridge, Massachusetts

Fellowship

  • 2003, Fellowship, Medical Oncology, University of Arizona Cancer Center, Tucson, Arizona

Residency

  • 2001, Residency, Internal Medicine, Mayo Clinic, Rochester, Minnesota

Professional Experience

  • 2025–Present, Professor and Section Chief of Sarcoma Medical Oncology, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California
  • 2025–Present, Vice Chair, Department of Medical Oncology, City of Hope Clinical Network, City of Hope, Duarte, California
  • 2021–2025, Professor of Medicine, Clinician/Scholar Pathway, Fred Hutch Cancer Center, Seattle, Washington
  • 2015–2021, Associate Member, Clinician/Scholar Pathway, Fred Hutch Cancer Center, Seattle, Washington
  • 2010–2015, Associate Professor of Medicine, Section of Hematology and Oncology, University of Arizona, Tucson, Arizona

Publications

  • Tate WR, Abraham I, Cranmer LD. Center-Specific Modeling Predicts Cancer Trial Accrual More Accurately Than Investigators and Random Effects Modeling at 16 Cancer Centers. JCO Clin Cancer Inform. 2019 Jun;3:1-12. doi: 10.1200/CCI.19.00005. PMID: 31173517.
  • Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, Trieselmann K, Copeland VC, Zhang S, Black G, McDonnell S, Gregory J, Johnson R, Moore R, Jones RL, Cranmer LD. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Nov 1;6(11):1778-1782. doi: 10.1001/jamaoncol.2020.3689. PMID: 32910151; PMCID: PMC7489365.
  • Cranmer LD, Lu Y, Heise RS, Ballman KV, Loggers ET, Pollack SM, Wagner MJ, Reinke DK, Schöffski P, Tap WD. Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406). Clin Cancer Res. 2023 Mar 14;29(6):1068-1076. doi: 10.1158/1078-0432.CCR-22-1564. PMID: 36622694.
  • Cranmer LD, Hess LM, Sugihara T, Muntz HG. Cardiac events among patients with sarcoma treated with doxorubicin by method of infusion: A real-world database study. Cancer Rep (Hoboken). 2023 Jan;6(1):e1681. doi: 10.1002/cnr2.1681. Epub 2022 Jul 18. PMID: 35852051; PMCID: PMC9875654.
  • Cranmer LD, Konnick EQ, Yoshida JR, Jacobson AL, Malik BA, Mogal H, Sullivan LB, Handfrod CL, Pritchard CC, Dubard-Gault ME. Combined Germline and Mosaic SDHA Mutation Is Associated With a Multicancer Syndrome Including Neuroblastoma, Renal Cancer, and Multifocal GI Tumor. JCO Precis Oncol. 2024 Jun;8:e2300455. doi: 10.1200/PO.23.00455. PMID: 38885448; PMCID: PMC11371076.
  • Lynch MM, Al-Marayaty R, Obeidin F, Alexiev BA, Chen EY, Viveiros P, Schroeder BA, Hudkins K, Fan TM, Redman MW, Baker KK, Jour G, Cranmer LD, Pollack SM. B7-H3 is widely expressed in soft tissue sarcomas. BMC Cancer. 2024 Oct 30;24(1):1336. doi: 10.1186/s12885-024-13061-4. PMID: 39478506; PMCID: PMC11523878.
  • Wagner MJ, Pimenta EM, Sweeney NW, Loggers ET, Roberts JL, Brinkman E, Chen EY, Ricciotti R, Haddox CL, Berg R, Yilma B, Stoppler MC, Chen JL, Cranmer LD. Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets. JCO Precis Oncol. 2025 Mar;9:e2400592. doi: 10.1200/PO-24-00592. Epub 2025 Mar 21. PMID: 40117529; PMCID: PMC11949235.
  • Biermann JS, Hirbe A, Ahlawat S, Bernthal NM, Binitie O, Boles S, Brigman B, Callan AK, Cipriano C, Cranmer LD, Davis J, Donnelly E, Ferguson M, Graham A, Groundland J, Hess M, Hiniker SM, Hoover-Regan ML, Hornick JL, Jonard B, Kuechle JB, Lindskog D, Mayerson JL, McGarry SV, Morris CD, Olson D, Rose PS, Santana VM, Satcher RL, Schwartz H, Shulman RM, Thorpe SW, Wilky BA, Wustrack RL, Yoon J, Hang LE, Jones F, Sansone N, Lyons M. Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Apr;23(4):e250017. doi: 10.6004/jnccn.2025.0017. PMID: 40203873.
  • Mor E, Apte S, Mitchell C, Nessim C, Almond M, Vincenzi B, Lopez JAG, Cranmer L, Wagner MJ, Nissan A, Abreu MH, Albertsmeier M, Knoblauch M, Barlow A, Keung EZ, Grignani G, Hornick JL, Gronchi A, Gyorki DE. Correction: Natural History of Primary Retroperitoneal Extra-Visceral Perivascular Epithelioid Cell Tumors (PEC): A Study from Transatlantic and Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Surg Oncol. 2025 Oct;32(10):7843. doi: 10.1245/s10434-025-18021-1. Erratum for: Ann Surg Oncol. 2025 Oct;32(10):7817-7828. doi: 10.1245/s10434-025-17787-8. PMID: 40730732; PMCID: PMC12454578.
  • Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Polson KM, Yalamanchili S, DeBoer C, Ding L, Schmid AN, Navarro WH, Kwiatkowski DJ, Dickson MA. A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors. Future Oncol. 2026 Jan;22(1):1-13. doi: 10.1080/14796694.2025.2574811. Epub 2025 Dec 22. PMID: 41424265; PMCID: PMC12773610.
  • Fabbroni C, Johnston EW, Sanfilippo R, Strauss DC, Bonvalot S, Spalek M, Van Houdt WJ, Ford SJ, Lee KW, Salawu A, Swallow CJ, Bae S, Gyorki DE, Raut CP, Mullinax JE, Albertsmeier M, Cananzi F, Konieczkowski D, Grignol VP, Pennacchioli E, Solli P, Napolitano A, Blasi ED, Wilkinson M, Stacchiotti S, Tzanis D, Rutkowski P, Bouhadiba T, Schrage YM, Sherriff J, Wang J, Callegaro D, Farma JM, Fiore M, Gervais MK, Gladdy RA, Nessim C, Roland CL, Cranmer L, Lee TY, Patel S, von Mehren M, Wagner AJ, Sicklick J, Gronchi A, Tseng WW. Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic retroperitoneal sarcoma working group (TARPSWG). Cancer Treat Rev. 2026 Jan 4;143:103086. doi: 10.1016/j.ctrv.2025.103086. Epub ahead of print. PMID: 41506129.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Provider listen carefully to you
5.0
Show respect for what you say
4.9
Provider explain in way you understand
4.9
Spend enough time with you
4.8
Recommend this provider office
4.8
Know important info medical history
4.8
Rate provider 0-10
04/27/26
Great visit - Dr Cranmer explained test results and upcoming testing very clearly so I could understand my current status and next steps completely. - Verified patient
03/26/26
Excellent - Verified patient
03/26/26
Excellent - Verified patient
03/26/26
City of Hope is the best!!! I wish I had started my initial treatment here!! [...] - Verified patient
03/26/26
Dr Cranmer was easy to talk to and even though I'm facing a horrible and scary diagnosis, he calmed some of my fears with his fabulous bed-side manner. I left feeling somewhat more hopeful but regardless, knowing I trust his judgment and expertise! - Verified patient